FDA Approves Lilly's Oral GLP-1 for Obesity, Delivering 5% to 10% Weight Loss
Updated
Updated · Pharmacy Times · May 20
FDA Approves Lilly's Oral GLP-1 for Obesity, Delivering 5% to 10% Weight Loss
5 articles · Updated · Pharmacy Times · May 20
Adults with obesity or overweight can now use Eli Lilly's once-daily orforglipron, sold as Foundayo, as the first oral GLP-1 in its class approved without fasting or water restrictions.
Phase 3 data backing the approval showed HbA1c reductions of about 1.2% to 1.6% in type 2 diabetes studies and average weight loss of 5% to 10% of baseline body weight.
Its small-molecule, nonpeptide design allows absorption regardless of food or water intake, potentially improving adherence versus peptide-based oral GLP-1 drugs with stricter dosing rules.
Common side effects matched the GLP-1 class—mainly nausea, vomiting and diarrhea—while warnings include pancreatitis risk, dehydration-related kidney issues and hypoglycemia when combined with insulin or secretagogues.
The approval broadens options for patients unwilling or unable to use injectables and positions orforglipron for possible expansion into diabetes and other conditions already under study.
How might this new weight-loss drug completely reshape the global food and beverage industry?
Lilly's new pill promises easy weight loss, but what's the hidden cost if you ever stop taking it?
Could a simple DNA test predict your success on this new daily weight-loss pill?
Foundayo (Orforglipron) FDA Approval: Flexible Oral GLP-1 Pill Delivers 11% Weight Loss and New Access for Obesity Care in 2026
Overview
On April 1, 2026, Eli Lilly achieved a major milestone with FDA approval of Foundayo, the first oral, small-molecule GLP-1 receptor agonist for adults with obesity or overweight and related conditions. This approval marks a new era in chronic weight management by meeting the growing demand for more accessible and convenient obesity treatments. Foundayo stands out for its flexible dosing regimen, allowing patients to take it at any time, with or without food or water. This flexibility, combined with its oral form, offers a unique advantage over earlier options like Novo Nordisk’s Wegovy pill, making weight management simpler for many people.